Efinopegdutide

**Semantic type:** Pharmacologic Substance

**Definition:** A synthetic peptide of oxyntomodulin conjugated to the constant region of human immunoglobulin G4 (IgG4) and dual glucagon-like peptide-1 (GLP-1)/glucagon receptor co-agonist, with potential weight reducing and anti-diabetic activities and that may potentially be used for the treatment of non-alcoholic steatohepatitis (NASH). Upon subcutaneous administration, efinopegdutide targets, binds to, and activates GLP-1 and glucagon receptors. GLP-1 receptor activation increases glucose-dependent insulin release and reduces the elevated glucagon secretion by inhibiting alpha cells of the pancreas and slows gastric emptying. This lowers the postprandial glucose level. In the brain, the binding to and activation of GLP-1 receptor suppresses appetite, which decreases caloric intake and lowers body weight. Glucagon receptor agonism further stimulates insulin secretion, decreases glucagon production, and increases satiety. This leads to a reduction in food intake, and improves blood sugar control and weight loss. Reduction in weight by efinopegdutide also indirectly reduces liver fat content (LFC), reduces NASH-induced hepatic inflammation and may prevent liver damage. In addition, glucagon receptor activation directly stimulates fatty acid oxidation and reduces lipogenesis, which further reduces LFC and hepatic inflammation.

**Synonyms:** - EFINOPEGDUTIDE - HM 12525A - HM-12525A - HM12525A - JN J64565111 - JNJ-64565111 - JNJ64565111 - MK 6024 - MK-6024 - MK6024